Recent Advances (2020–2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies—A Comprehensive Review
Cancer Management and Research · 2026-08 · Volume 18 · 1-23
DOI: 10.2147/cmar.s622575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Management and Research, 2026-08. Verfasst von Jiaxin Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thyroid Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, People's Republic of China.
ORCID-Profile: Jiaxin Zhao
Zitieren
APA
Zhao, J., Li, D., Yang, S., & Ma, X. (2026). Recent Advances (2020–2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies—A Comprehensive Review. Cancer Management and Research, Volume 18, 1-23. https://doi.org/10.2147/cmar.s622575
Vancouver
Zhao J, Li D, Yang S, Ma X. Recent Advances (2020–2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies—A Comprehensive Review. Cancer Management and Research. 2026;Volume 18:1-23. doi:10.2147/cmar.s622575
BibTeX
@article{Zhao2026,
author = {Zhao, Jiaxin and Li, Donghai and Yang, Shaofeng and Ma, Xin},
title = {Recent Advances (2020–2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies—A Comprehensive Review},
journal = {Cancer Management and Research},
year = {2026},
volume = {Volume 18},
pages = {1--23},
doi = {10.2147/cmar.s622575}
}
EUVIMED